We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

By LabMedica International staff writers
Posted on 18 Apr 2025

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. More...

They are also integral in forensic investigations and biosensing. Fluorophores have been utilized by scientists to highlight cells and tissues under specialized microscopes, making even the smallest details visible. These molecules also play a crucial role in tracking diseases, studying cellular functions, and assisting in the diagnosis of various health conditions. Now, researchers have developed tiny, clay-based materials known as fluorescent polyionic nanoclays, which can be tailored for numerous applications, including improving medical tests.

These fluorescently labeled nanoclays, created by researchers at the University of Missouri-Columbia (Columbia, MO, USA), exhibit an exceptional brightness of 7,000 brightness units when normalized by volume, marking the highest levels ever recorded for a fluorescent material. This increased brightness makes these materials highly effective for sensitive optical detection methods, leading to stronger analytical signals and improved detection. These enhancements open up new possibilities for advanced sensors and contrast agents in medical imaging. Published in Chemistry of Materials, the study emphasizes the versatility of these nanoclays, which can be adapted to a variety of applications. They have a high degree of functionality, allowing for precise control over the number and type of fluorescent molecules attached to their surfaces. This capability provides a flexible platform where the optical and physicochemical properties of the nanoclays can be finely tuned by selecting and attaching specific molecules.

One of the key features of these nanoclays is their ability to be easily customized, making them suitable for diverse applications in different fields. Initial tests suggest that these materials are safe for medical use, potentially enabling doctors to see inside the body with greater clarity. Although fluorescence remains the primary focus of current research, the team plans to further explore the customization of these nanoclays by incorporating other molecules, such as amino acids, antibodies, DNA aptamers, and ligands for selective metal binding. This opens up opportunities for applications beyond just imaging and sensing. These materials could also play a significant role in drug delivery, improving medical tests, monitoring diseases, and aiding in cancer treatment.


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.